BiotechTube

PD-L1/IDO Peptide Vaccine + Pembrolizumab

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

Conditions

High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8

Trial Timeline

Apr 19, 2023 → Dec 1, 2026

NCT ID
NCT05843448

About PD-L1/IDO Peptide Vaccine + Pembrolizumab

PD-L1/IDO Peptide Vaccine + Pembrolizumab is a phase 1 stage product being developed by IO Biotech for High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05843448. Target conditions include High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8.

What happened to similar drugs?

6 of 20 similar drugs in High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma were approved

Approved (6) Terminated (7) Active (9)
✅Bunazosin + Doxazosin + ValsartinEisaiApproved
✅AliskirenNovartisApproved
✅Aliskiren and HCTZNovartisApproved
✅Aspirin 100 mg + PlaceboBayerApproved
✅Escitalopram + Placebo oral tabletLundbeckApproved
✅losartan potassium + Comparator: PlaceboOrganonApproved
❌Edoxaban + ASADaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05843448Phase 1Recruiting

Competing Products

20 competing products in High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
32
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
14
Sepantronium BromideCothera BiosciencePhase 2
29
Edoxaban + ASADaiichi SankyoPhase 3
32
olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
36
Bunazosin + Doxazosin + ValsartinEisaiApproved
43
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
21
DSP-0390Sumitomo PharmaPhase 1
33
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
36
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR3680 + PlaceboJiangsu Hengrui MedicinePhase 3
47
Camrelizumab、Rivoceranib + CamrelizumabJiangsu Hengrui MedicinePhase 2
35
Mirvetuximab soravtansine + CarboplatinAbbViePhase 2
39
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
32
Mirvetuximab SoravtansineAbbViePhase 2
42
Zibotentan/Dapagliflozin + DapagliflozinAstraZenecaPhase 2
42
AZD5718 IR tablet + AZD5718 oral suspension + Rosuvastatin tabletAstraZenecaPhase 1
29
Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3
40
Olaparib Pill + AZD6738AstraZenecaPhase 2
35
DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3
40